Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darunavir/Ritonavir 900/100 mg Once Daily Simplification Strategy
NCT00611039Phase 4Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Feb 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darunavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoint: Proportion of patients with HIV-1 viral load < 50 copies /mL at 48 weeks. Started Feb 2008; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00611039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611039.